Year |
Citation |
Score |
2023 |
Mendoza-Munoz PL, Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Dynlacht JR, Garrett JE, Turchi JJ. Ku-DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks. Nar Cancer. 5: zcad003. PMID 36755959 DOI: 10.1093/narcan/zcad003 |
0.752 |
|
2022 |
Turchi JJ, Pawelczak KS, Weinfeld M, McHugh PJ. Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases. Frontiers in Oncology. 12: 1023500. PMID 36237323 DOI: 10.3389/fonc.2022.1023500 |
0.797 |
|
2022 |
Kelm JM, Samarbakhsh A, Pillai A, VanderVere-Carozza PS, Aruri H, Pandey DS, Pawelczak KS, Turchi JJ, Gavande NS. Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. Frontiers in Oncology. 12: 850883. PMID 35463312 DOI: 10.3389/fonc.2022.850883 |
0.837 |
|
2022 |
VanderVere-Carozza PS, Gavande NS, Jalal SI, Pollok KE, Ekinci E, Heyza J, Patrick SM, Masters A, Turchi JJ, Pawelczak KS. Targeting Replication Protein A for Cancer Therapy. Frontiers in Oncology. 12: 826655. PMID 35251993 DOI: 10.3389/fonc.2022.826655 |
0.743 |
|
2021 |
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell. 81: 3227. PMID 34358459 DOI: 10.1016/j.molcel.2021.07.015 |
0.608 |
|
2021 |
Par S, Vaides S, VanderVere-Carozza PS, Pawelczak KS, Stewart J, Turchi JJ. OB-Folds and Genome Maintenance: Targeting Protein-DNA Interactions for Cancer Therapy. Cancers. 13. PMID 34283091 DOI: 10.3390/cancers13133346 |
0.781 |
|
2021 |
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Jonkers J, Johnson N, Turchi JJ, Rothenberg E, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell. PMID 34216544 DOI: 10.1016/j.molcel.2021.06.011 |
0.69 |
|
2020 |
Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Mendoza-Munoz P, Vernon TL, Hanakahi LA, Summerlin M, Dynlacht JR, Farmer AH, Sears CR, Nasrallah NA, Garrett J, Turchi JJ. Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku-DNA interaction. Nucleic Acids Research. PMID 33119767 DOI: 10.1093/nar/gkaa934 |
0.857 |
|
2020 |
Sriramkumar S, Matthews TD, Ghobashi AH, Miller SA, VanderVere-Carozza PS, Pawelczak KS, Nephew KP, Turchi JJ, O'Hagan HM. Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A is Mediated by Replication Protein A in Ovarian Cancer. Molecular Cancer Research : McR. PMID 32801161 DOI: 10.1158/1541-7786.Mcr-20-0396 |
0.831 |
|
2020 |
Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Vernon TL, Jordan MR, Turchi JJ. Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors. Acs Medicinal Chemistry Letters. 11: 1118-1124. PMID 32550990 DOI: 10.1021/Acsmedchemlett.9B00440 |
0.835 |
|
2019 |
Turchi JJ, VanderVere-Carozza PS, Gavande NS, Pawelczak KS. Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku Cancer Research. 79: 1301-1301. DOI: 10.1158/1538-7445.Am2019-1301 |
0.867 |
|
2019 |
Turchi J, Pawelczak KS, Gavande N, VanderVere-Carozza PS. Abstract A095: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A095 |
0.863 |
|
2018 |
Turchi JJ, Gavande N, VanderVere-Carozza PS, Vernon T, Pawelczak KS. Abstract LB-A11: Targeting DNA-PK and the DNA damage response via small molecule Ku inhibitors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A11 |
0.876 |
|
2017 |
Pawelczak KS, Gavande NS, VanderVere-Carozza PS, Turchi JJ. Modulating DNA Repair Pathways to Improve Precision Genome Engineering. Acs Chemical Biology. PMID 29210569 DOI: 10.1021/Acschembio.7B00777 |
0.799 |
|
2017 |
Gavande NS, VanderVere-Carozza P, Mishra AK, Vernon TL, Pawelczak KS, Turchi JJ. Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. Journal of Medicinal Chemistry. PMID 28933851 DOI: 10.1021/Acs.Jmedchem.7B00780 |
0.782 |
|
2017 |
Pawelczak KS, Gavande N, VanderVere-Carozza P, Turchi J. Abstract B34: Development of novel small molecule inhibitors targeting DNA repair proteins Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B34 |
0.835 |
|
2017 |
Turchi JJ, Gavande N, VanderVere-Carozza P, Vernon T, Pawelczak K. Abstract LB-119: Targeting DNA-PK via small molecule inhibitors of the Ku-DNA interaction Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-119 |
0.881 |
|
2017 |
Gavande NS, VanderVere-Carozza PS, Vernon TL, Pawelczak K, Turchi JJ. Abstract 1416: Development of small molecule inhibitors for cancer therapy by targeting RPA and XPA nucleotide excision repair proteins Cancer Research. 77: 1416-1416. DOI: 10.1158/1538-7445.Am2017-1416 |
0.666 |
|
2016 |
Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacology & Therapeutics. PMID 26896565 DOI: 10.1016/J.Pharmthera.2016.02.003 |
0.855 |
|
2014 |
Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, Matei D, Turchi JJ, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6504-16. PMID 25316809 DOI: 10.1158/1078-0432.Ccr-14-1553 |
0.711 |
|
2013 |
Tang J, Fang F, Wang Y, Taverna P, Miller DFB, Choy G, Azab M, Matei D, Pawelczak KS, VanderVere-Carozza P, Wagner M, Turchi JJ, Nephew KP. Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Cancer Research. 73: 4623-4623. DOI: 10.1158/1538-7445.Am2013-4623 |
0.726 |
|
2012 |
Bennett SM, Woods DS, Pawelczak KS, Turchi JJ. Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80. International Journal of Biochemistry and Molecular Biology. 3: 36-45. PMID 22509479 |
0.801 |
|
2011 |
Pawelczak KS, Bennett SM, Turchi JJ. Coordination of DNA-PK activation and nuclease processing of DNA termini in NHEJ. Antioxidants & Redox Signaling. 14: 2531-43. PMID 20698792 DOI: 10.1089/Ars.2010.3368 |
0.85 |
|
2010 |
Pawelczak KS, Turchi JJ. Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair. Dna Repair. 9: 670-7. PMID 20347402 DOI: 10.1016/J.Dnarep.2010.03.002 |
0.796 |
|
2008 |
Pawelczak KS, Turchi JJ. A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining. Nucleic Acids Research. 36: 4022-31. PMID 18515838 DOI: 10.1093/Nar/Gkn344 |
0.855 |
|
2008 |
Rahal EA, Henricksen LA, Li Y, Turchi JJ, Pawelczak KS, Dixon K. ATM mediates repression of DNA end-degradation in an ATP-dependent manner. Dna Repair. 7: 464-75. PMID 18207464 DOI: 10.1016/J.Dnarep.2007.12.003 |
0.749 |
|
2005 |
Pawelczak KS, Andrews BJ, Turchi JJ. Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Research. 33: 152-61. PMID 15640450 DOI: 10.1093/nar/gki157 |
0.84 |
|
Show low-probability matches. |